<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04878276</url>
  </required_header>
  <id_info>
    <org_study_id>VEKODIH</org_study_id>
    <nct_id>NCT04878276</nct_id>
  </id_info>
  <brief_title>Comparative Head Lice Therapy With Dimet 5® vs. Hedrin® Once</brief_title>
  <acronym>VEKODIH</acronym>
  <official_title>Randomised, Investigator-blinded, Controlled, Multicentre Comparative Study on the Treatment of Head Lice Infestation With 2 Dimeticone Preparations With Different Application Times and Compositions: Dimet 5® (100% Dimeticon) Versus Hedrin® Once Liquid Gel (4% Dimeticon + Nerolidol)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Infectopharm Arzneimittel GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Infectopharm Arzneimittel GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, investigator-blinded, controlled, multicenter comparative study on the treatment&#xD;
      of acute head lice infestation in children with 2 dimeticone preparations with different&#xD;
      application times and compositions: Dimet 5® (100% dimeticone) versus Hedrin® Once Liquid Gel&#xD;
      (4% dimeticone + nerolidol) with treatment success assessment via freedom from infestation of&#xD;
      live head lice at final examination at V2, i.e. day 19 after first treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from infestation</measure>
    <time_frame>Day 17 to 21</time_frame>
    <description>Freedom from infestation of live head lice at the final examination (V2)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Head Lice Infestation</condition>
  <condition>Pediculosis Capitis</condition>
  <condition>Lice</condition>
  <arm_group>
    <arm_group_label>Dimet 5</arm_group_label>
    <description>Dimet 5 is a certified medical device for the treatment of head lice infestation. It contains only (&quot;liquid&quot;) dimeticone oil and, when used correctly, enables physical killing of head lice and their eggs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hedrin Once Liquid Gel</arm_group_label>
    <description>Hedrin Once Liquid Gel is a certified medical product for the removal of head lice and nits. The liquid gel contains 4% dimethicone and nerolidol (Penetrol®).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dimet 5</intervention_name>
    <description>The application is carried out according to the enclosed instructions for use.</description>
    <arm_group_label>Dimet 5</arm_group_label>
    <arm_group_label>Hedrin Once Liquid Gel</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children ≥ 6 months with acute head lice infestation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute head lice infestation&#xD;
&#xD;
          -  Age ≥ 6 months&#xD;
&#xD;
          -  Adequate informed consent for study participation:&#xD;
&#xD;
               -  Age-appropriate informed consent and verbal informed consent from the patient (if&#xD;
                  capable of both).&#xD;
&#xD;
               -  Written informed consent from the legal guardian(s) (written and verbal).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults (≥ 18 years of age)&#xD;
&#xD;
          -  Known hypersensitivity to any component of the test or comparator product.&#xD;
&#xD;
          -  Scalp lice therapy in the previous 2 weeks (with an appropriate drug or medical&#xD;
             device).&#xD;
&#xD;
          -  Severe disease of the scalp or injuries/open wounds on the hairy head&#xD;
&#xD;
          -  Secondary infection in the area of the hairy head&#xD;
&#xD;
          -  Treatment with cotrimoxazole or trimethoprim in the last 4 weeks or new treatment to&#xD;
             be initiated now&#xD;
&#xD;
          -  Other relevant reasons, e.g. diseases or dysfunctions, which, in the opinion of the&#xD;
             investigator, militate against the inclusion of the patient in the study (including&#xD;
             risk factors for severe COVID-19 disease in the case of SARS-CoV-2 infection)&#xD;
&#xD;
          -  Simultaneous participation of another household member in the trial.&#xD;
&#xD;
          -  Previous participation in this trial&#xD;
&#xD;
          -  Participation in another trial within the last 30 days&#xD;
&#xD;
          -  Inability of the legal guardian(s) to understand the study content and instructions.&#xD;
&#xD;
          -  Limited legal capacity of the legal guardian(s)&#xD;
&#xD;
          -  Apparent unreliability or unwillingness to cooperate on the part of the legal&#xD;
             guardian(s)&#xD;
&#xD;
          -  Known alcohol, medication or drug dependency of the legal guardian(s)&#xD;
&#xD;
          -  Dependence of the patient or guardian on the sponsor or investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Beril Wachall</last_name>
    <email>studien@infectopharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dr. med. Thilo Heising</name>
      <address>
        <city>Aalen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Gilb/Bauer/von Bentzel</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Gilb, DM</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. med. Omar Esteban Fernandez Salgueiro</name>
      <address>
        <city>Balingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. med. Martin Wiesner</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. med. Friedrich Kaiser</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. med. Ludwig Stapenhorst</name>
      <address>
        <city>Hürth</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludwig Stapenhorst, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. med. Susanne Ludwig</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. med. Katrin Biebach</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Simon Traub</name>
      <address>
        <city>Schweigen-Rechtenbach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lice Infestations</mesh_term>
    <mesh_term>Parasitic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

